Coriolan Lebreton

Immuno-molecular features associated with exceptional recurrence–free survivorship from Ovarian Cancer in the pre-PARP era

Félix Blanc–Durand, Elisa Yaniz Galende, Gwénaël Ferron, Marie‐Christine Kaminsky et autres

High-grade serous ovarian cancer (HGSOC) remains a leading cause of gynecological cancer mortality, with only <15% of patients achieving long-term, relapse-free survival. Using data from the VIVROVAIRE (NCT03418844) and CHIVA (NCT03418844) clinical trials, this study investigated the molecular and immunophenotypic characteristics of …

fr (code pays fourni par la source)

Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2024–2025 : prise en charge du cancer de l’endomètre métastatique et/ou en rechute

Lauriane Eberst, Corinne Jeanne, Guillaume Bataillon, Antoine Angelergues et autres

fr, lu (code pays fourni par la source)

ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, A. Leary, Aurelia Baures et autres

PURPOSE: ctDNA may offer a noninvasive means to evaluate tumor response and anticipate disease dynamics before radiologic changes in advanced endometrial carcinoma. EXPERIMENTAL DESIGN: This ancillary analysis included patients from the multicenter, randomized, phase II GINECO-UTerin OLAparib (UTOLA) trial (NCT03745950) evaluating olaparib/placebo …

fr, in, lu (code pays fourni par la source)